Later onset of vitiligo in patients with melanoma who initiated anti-PD-1 therapy was associated with a lower 3-year mortality rate.

MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” anti-PD-1-IL-2 Superkine (anti-PD1-IL-2SK), engineered to precisely deliver clinically ...

Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, today announced that preclinical data from its IL ...

The results of the EVOKE and EVOKE+ trials were comprehensive in showing oral semaglutide’s lack of clinical efficacy for ...

Initiated a formal process to monetize assets Implemented a restructuring plan to significantly reduce operating expenses and ...

Alpha synuclein is a presynaptic protein that, when misfolded, contributes to neuronal degeneration and the progression of ...

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in the Raymond James 2026 ...

We explore what allosteric modulators are, their benefits and drawbacks, and which candidates are currently advancing through ...

XTX501, a potential best-in-class bispecific PD-1 / masked IL-2, on track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 Advancing potential first-in-class ...

Researchers have found that amlodipine, a calcium-channel blocker prescribed to tens of millions of people for high blood ...

Week Study to Evaluate One-Step Dose Titration to 48 mg and Two-Step Dose Titration to 64 mg in Obese Otherwise Healthy Adults CAMBRIDGE, Mass., March 18, 2026 ...